2-(4-(pyridin-3-yl)phenyl)propan-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(4-(pyridin-3-yl)phenyl)propan-2-amine
• 英文别名: 2-(4-Pyridin-3-ylphenyl)propan-2-amine；2-(4-pyridin-3-ylphenyl)propan-2-amine
• 化学式: C₁₄H₁₆N₂
• 分子量: 212.294
• InChiKey: NPOBSNISZPYGSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE<br/>[FR] PYRIMIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016057762A1

  公开（公告）日：2016-04-14

  The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

  本发明涉及一种化合物，其化学式为I，能够抑制HIF prolyl羟基化酶，用于增强内源性促红细胞生成素的产生，并用于治疗与内源性促红细胞生成素减少相关的疾病，如贫血等疾病，以及包含此类化合物和药用载体的药物组合物。
• SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170247336A1

  公开（公告）日：2017-08-31

  The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
• [EN] SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE<br/>[FR] PYRIMIDINES SUBSTITUÉES UTILISÉES COMME INHIBITEURS DE LA HIF PROLYL HYDROXYLASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016054804A1

  公开（公告）日：2016-04-14

  The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.